Fig. 2: GIE prevalence across cancer types.

a, Total number of uniformly processed WGS samples included in the study from the metastatic (Hartwig) and primary (PCAWG) datasets. b, Number of processed samples from each cohort across cancer types with at least 15 samples in both datasets. c, Top, cancer type-specific proportion of metastatic samples with GIE alterations across the six pathways and the combined group. Bottom, pan-cancer proportion and number of samples with GIE alterations in the metastatic group. d, Analogous for the primary dataset. Boxplots: the center line is the median, the box limits the first and third quartiles and the whiskers the lowest/highest datapoints at the first quartile ± 1.5 × the interquartile range (IQR). The ticks on the x axis label numbers representing the associated immune escape pathway, relative to Fig. 1a. e, Radar plots representing, using a shaded area, the cohort and cancer type-specific fraction of samples with GIE alterations in metastatic PANET (top) and primary kidney chromophobe (KICH, bottom) tumors across the six pathways from Fig. 1a. f, Analogous representation for, from top-left in a clockwise direction, metastatic DLBCL, primary DLBCL, primary COREAD and metastatic UCEC tumors. amp., amplification; del., deletion; pres., presentation; reg., regulation. The remaining cancer-type acronyms are displayed in b.